Literature DB >> 23875516

Prevalence of drug resistance and associated mutations in a population of Hiv-1+ Puerto Ricans in 2005.

Luis A Cubano1, Luz Cumba, Lycely C del Sepúlveda-Torres, Nawal Boukli, Eddy Ríos-Olivares.   

Abstract

This is a continuation of our efforts to maintain a record of the evolution of HIV-1 infection in Puerto Rico by monitoring the expression levels of antiretroviral resistance-associated mutations. Samples from 2005 were analyzed (458: 270 males, 137 females, 51 anonymous), using the TRUGENE HIV-1 Genotyping Kit and the OpenGene DNA Sequencing System. Results show that 60.1% of males and 50.2% of females had HIV-1 with resistance to at least one medication. The average number of HIV mutations in males was 6.27, while the average number of HIV mutations in females was 5.49. The highest levels of resistance were to Zalcitabine, Lamivudine, and Stavudine. The reverse transcriptase mutations with the highest frequency of expression were M184V, K103N and D67N. Protease mutations with the highest rate of expression were L63P, M361 and L90M. Significant differences between men and women were recorded in the levels of HIV-1 expressed mutations and resistance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 23875516      PMCID: PMC4556367     

Source DB:  PubMed          Journal:  Bol Asoc Med P R        ISSN: 0004-4849


  26 in total

1.  Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey.

Authors:  Sabine Yerly; Viktor von Wyl; Bruno Ledergerber; Jürg Böni; Jörg Schüpbach; Philippe Bürgisser; Thomas Klimkait; Martin Rickenbach; Laurent Kaiser; Huldrych F Günthard; Luc Perrin
Journal:  AIDS       Date:  2007-10-18       Impact factor: 4.177

2.  Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team.

Authors:  J S Currier; C Spino; J Grimes; C B Wofsy; D A Katzenstein; M D Hughes; S M Hammer; D J Cotton
Journal:  J Acquir Immune Defic Syndr       Date:  2000-08-01       Impact factor: 3.731

3.  Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care?

Authors:  A Mocroft; M J Gill; W Davidson; A N Phillips
Journal:  J Acquir Immune Defic Syndr       Date:  2000-08-15       Impact factor: 3.731

4.  Racial differences in changes of metabolic parameters and body composition in antiretroviral therapy-naive persons initiating antiretroviral therapy.

Authors:  Cynthia L Gibert; Judith C Shlay; Shweta Sharma; Glenn Bartsch; Grace Peng; Carl Grunfeld
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

Review 5.  Gender differences in the treatment of HIV infection.

Authors:  Marco Floridia; Marina Giuliano; Lucia Palmisano; Stefano Vella
Journal:  Pharmacol Res       Date:  2008-07-30       Impact factor: 7.658

Review 6.  Drug-resistant human immunodefiency virus.

Authors:  M J Kozal
Journal:  Clin Microbiol Infect       Date:  2009-01       Impact factor: 8.067

7.  Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study).

Authors:  Ellen M Tedaldi; Judith Absalon; Avis J Thomas; Judith C Shlay; Mary van den Berg-Wolf
Journal:  J Acquir Immune Defic Syndr       Date:  2008-04-01       Impact factor: 3.731

8.  Gender differences in discontinuation of antiretroviral treatment regimens.

Authors:  Mirjam-Colette Kempf; Maria Pisu; Anastasiya Dumcheva; Andrew O Westfall; J Michael Kilby; Michael S Saag
Journal:  J Acquir Immune Defic Syndr       Date:  2009-11-01       Impact factor: 3.731

9.  Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.

Authors:  Robert S Hogg; David R Bangsberg; Viviane D Lima; Chris Alexander; Simon Bonner; Benita Yip; Evan Wood; Winnie W Y Dong; Julio S G Montaner; P Richard Harrigan
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

10.  Predictors of disease progression in HIV infection: a review.

Authors:  Simone E Langford; Jintanat Ananworanich; David A Cooper
Journal:  AIDS Res Ther       Date:  2007-05-14       Impact factor: 2.250

View more
  3 in total

1.  Prevalence of Drug Resistance and Associated Mutations in a Population of HIV-1(+) Puerto Ricans: 2006-2010.

Authors:  Lycely Del C Sepúlveda-Torres; Alexandra De La Rosa; Luz Cumba; Nawal Boukli; Eddy Ríos-Olivares; Luis A Cubano
Journal:  AIDS Res Treat       Date:  2012-04-24

2.  A decade of viral mutations and associated drug resistance in a population of HIV-1+ Puerto Ricans: 2002-2011.

Authors:  Lycely Del C Sepúlveda-Torres; Lavanya Rishishwar; Maria Luisa Rogers; Eddy Ríos-Olivares; Nawal Boukli; I King Jordan; Luis A Cubano
Journal:  PLoS One       Date:  2017-05-11       Impact factor: 3.752

3.  Short Communication: Integrase Strand Transfer Inhibitors Drug Resistance Mutations in Puerto Rico HIV-Positive Individuals.

Authors:  Pablo López; Grissell Tirado; Andrea Arias; Raphael Sánchez; Elliott R Rodríguez-López; Vanessa Rivera-Amill
Journal:  Int J Environ Res Public Health       Date:  2021-03-08       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.